943513-64-2

Usage

Chemical structure

Contains a pyrrolidine ring, a chloromethyl group, and a morpholin-4-yl group.

Potential pharmaceutical applications

Has potential for use in drugs targeting central nervous system disorders.

Reactive functional group

Chloromethyl group allows for further chemical modifications.

Building block for drug design

Can be used as an intermediate or lead compound in the development of pharmaceuticals.

Solubility and bioavailability

Presence of the morpholin-4-yl group suggests potential for improved solubility and bioavailability properties.

Central nervous system activity

Chloromethyl and morpholin-4-yl groups are commonly found in drugs with central nervous system activity.

Upstream product

• 83909-55-1 methyl 2-(N-morpholino)-5-nitrobenzoate 
• 4031-84-9 methyl 5-amino-2-(4-morpholino)benzoate 
• 2965-22-2 methyl 2-fluoro-5-nitro-benzoate 
• 759456-60-5 (5-amino-2-morpholinophenyl)methanol 
• 1013071-74-3 1-(3-hydroxymethyl-4-morpholin-4-ylphenyl)pyrrolidin-2-one 

Downstream Products

• 845461-50-9 C₃₈H₄₃N₃O₅ 
• 852898-44-3 C₃₇H₄₃N₃O₅S 
• 943513-63-1 12-cyclohexyl-3-[2-morpholin-4-yl-5-(2-oxopyrrolidin-1-yl)benzyloxy]-6,7-dihydro-5-oxa-7a-azadibenzo[a,e]azulene-9-carboylic acid methyl ester 
• 1427550-16-0 methyl 13-cyclohexyl-3-{[2-(morpholin-4-yl)-5-(2-oxopyrrolidin-1-yl)benzyl]oxy}-6,7-dihydropyrazolo[5',1':2,3]imidazo[1,5-d][1,4]benzoxazepine-10-carboxylate 

Relevant academic research and scientific papers

Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: Benzimidazole and structurally related compounds bearing the 2-morpholinophenyl moiety

Following the discovery of JTK-109 (1) as a potent inhibitor of hepatitis C virus NS5B RNA-dependent RNA polymerase, [(a) Hirashima, S.; Suzuki, T.; Ishida, T.; Noji, S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda, S.; Hashimoto, H. J. Med. Chem. 2006, 49, 4721. (b) Hashimoto, H.; Mizutani, K.; Yoshida, A. Int. Patent Appl. WO 01/47883, 2001.] further studies toward the improvement of the cellular potency have been performed. A greater than 40-fold improvement was achieved through replacing the biphenyl moiety with a 2-morpholinophenyl group and the benzimidazole ring with the tetracyclic scaffold to afford compound 7 with an excellent replicon potency (EC50 = 7.6 nM).